The Commerce Commission has laid ten charges against Reckitt Benckiser (New Zealand), alleging it misled consumers about the nature, characteristics and suitability of its Nurofen products. In particular, the brand has been accused of marketing the same product, containing the same ingredients and active principle, as it was targeted for a specific pain, namely back pain, period pain and migraines.

In response, Nurofen NZ has released a statement emphasising that the products impacted represent less than five percent of NZ's overall Nurofen range.

“The Nurofen specific-pain range was launched in New Zealand to provide easy navigation of pain-relief within the grocery environment where pharmacy support is not available,” the statement read, adding that the packaging of these products was changed last March, and all products have the same RRP.